Synonyms :

IBP-6

Description :

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Catalog #:

350-07B

Source :

(BTI-Tn-5B1-4) High-5 Insect Cells*

Purity :

Greater than 95% by SDS-PAGE gel and HPLC analyses.

Endotoxin Level :

Endotoxin level is less than 0.1 ng per μg (1EU/μg).

Biological Activity :

Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED ₅₀ for this effect is 0.1 – 0.4 μg/ml.

AA Sequence :

RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG

PubMed Link :

IGF+AND+Binding+AND+Protein+AND+6

Country of Origin :

USA

Special Sizes:
Many products can be ordered in custom sizes. Please click here to contact with your request.

Usage:
For Research Use Only. Not for use in diagnostic or therapeutic procedures.